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Verisuonitus on välttämätöntä kudosten hyvinvoinnille, koska veren kuljettamien ravinteiden ja hapen 
täytyy tavoittaa kehon jokainen solu. Uusien verisuonten muodostusta, angiogeneesia, tarvitaan 
sikiön kehityksen ja kasvun aikana, samoin haavan paranemiseen ja muihin fysiologisiin toimintoihin. 
Tapahtuessaan ilman tervettä fysiologista tarkoituksenmukaisuutta, se voi johtaa patologisiin 
prosesseihin, kuten tukemaan kasvaimen kasvua. 
 
Lääkkeiden kehityksessä angiogeneesilla ja sitä inhiboivilla lääkkeillä on suuri rooli. Uusia lääkkeitä 
tutkitaan ja kehitetään jatkuvasti erityisesti syöpäkasvaimia vastaan. Lisäksi saadaan jatkuvasti uutta 
tietoa ympäristökemikaaleista ja niiden negatiivisista vaikutuksista angiogeneesiin. Eläinkokeita 
käytetään yhä laajalti, vaikka niiden tulokset eivät välttämättä vastaa vaikutuksia ihmisellä. Tämän 
vuoksi tarve validoiduille ihmissoluilla tehdyille in vitro -malleille on kasvanut ja kiinnostus niiden 
kehittämiseen lisääntyy jatkuvasti. Vaikka in vitro -verisuonimallit eivät välttämättä kata joka vaihetta 
angiogeneesissa, ne kuitenkin mallintavat hyvin tärkeimmät osa-alueet, ovat helposti toistettavissa ja 
tulokset vastaavat paremmin vaikutuksia ihmisellä.  
 
Uusien verisuonten muodostamiseen tarvitaan endoteelisoluja, mutta putkimaisten rakenteiden 
muodostukseen tarvitaan myös ulkopuolista ärsykettä. Ihmisen napanuoran endoteelisolut (human 
umbilical vein endothelial cells, HUVECs) voivat muodostaa verisuonirakenteita, kun niitä viljellään 
maljalla oikeissa olosuhteissa. HUVEC-viljelmistä tehtyjen verisuonimallien avulla on mahdollista 
tutkia kemikaalien vaikutuksia angiogeneesiin. 
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1 INTRODUCTION 
 
 
1.1 Blood vessel formation 
 
Vasculature is essential to tissue welfare because it is needed to bring oxygen and other necessary 
molecules to tissues and organs. Blood vessel formation is needed during development, growth and 
wound healing. (Carmeliet et al., 2011) New blood vessels are derived from two sources: they can 
extend from pre-extending vessels (angiogenesis) or they can be derived from progenitor cells 
(vasculogesis). (Auerbach, 2008) 
 
1.1.1 Angiogenesis 
 
The primary cells needed for new blood vessel formation from pre-existing vessels are endothelial 
cells. These cells arise from pre-existing vessels and are released by breaking down or passing through 
extracellular matrix. Then they migrate, proliferate and reorganize. (Auerbach, 2008) Vascular 
endothelial growth factor (VEGF) is the most important angiogenic factor and angiogenesis is initiated 
by binding of VEGF to tyrosine kinase receptors present in endothelial cells surfaces. Binding initiates 
number of intracellular signal pathways, which leads to new blood vessel formation. (Friis et al., 2013) 
Trough the whole process there are interactions between endothelial cells and surrounding tissues, 
such as pericytes and smooth muscle cells. Angiogenesis is highly regulated by systemic factors such 
as hormones and cytokines in addition to hypoxia and shear stress. (Auerbach, 2008) Angiogenesis 
can also be pathological when it takes place in inappropriate place or if it supports tumor formation 
and growth. (Carmeliet et al., 2011) 
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1.1.2 Types of angiogenesis 
 
Sprouting angiogenesis means that endothelial cells basically grow towards angiogenic stimulus such 
as vascular endothelial growth factor (VEGF). Sprouting can add new blood vessels to tissues which 
did not have them earlier. The basic steps include endothelial cell proliferation, directed migration, 
tubulogenesis, vessel fusion, vessel pruning and pericyte stabilization. (Adair and Montani, 2010) 
 
In intussusceptive angiogenesis vessel wall extends into the lumen and causes vessel to split in two. 
This process is faster than sprouting because it does not require endothelial cell proliferation or 
migration. Both ways of angiogenesis happens in growing fetus and in adults but intussusceptive 
angiogenesis happens when fast capillary formation is needed. Intussusceptive angiogenesis mainly 
forms capillaries where capillaries already exist. (Adair and Montani, 2010) 
 
In cancer tumors tumor cells can hijack the existing vasculature or they can simply by themselves line 
blood vessels which is called vascular mimicry. Cancer stem-like cells can even generate tumor 
endothelium. (Adair and Montani, 2010) Angiogenesis is key process to tumor growth. Initially the 
growth of tumor is fed by nearby blood vessels but when tumor comes too big, lining blood vessels 
can not supply nutrients to whole tumor and angiogenesis occurs.  That is why angiogenesis inhibition 
is desirable target when thinking new anti-cancer drugs. (Cook and Figg, 2010)  
 
1.1.3 Vasculogenesis 
 
De novo formation of blood vessels means that blood vessel tubule network is formed from stem 
cells. That happens mainly in extraembryonic and intraembryonic tissues of embryos. At the end of 
vasculogenesis, endothelial cells are lining the luminal surface of vessels and they are formed from 
angioblasts, which are derived from mesodermal stem cells. Vasculogenesis is dynamic process and it 
involves cell-cell and cell-extracellular matrix (ECM) interactions which include different growth 
factors. (Adair and Montani, 2010) Veins and arteries have both they own signal pathways (Carmeliet 
et al., 2011). 
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1.2 hASCs 
 
Human adipose stromal cells (hASCs), isolated from adipose tissue as stromal-vascular fraction are 
pluripotent cells. In adipose tissue ASCs are localized in peri-endothelial layer of blood vessels and 
they are functionally and phenotypically equivalent to pericytes of microvessels. They secrete 
molecules which promotes endothelial cell survival and proliferation including vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF) and granulocyte macrophage colonystimulating 
factor (GM-CSF). They also stabilize endothelial network in angiogenesis models. (Merfeld-Clauss et 
al., 2010) 
 
1.3 Angiogenesis assays 
 
Angiogenesis studies have become important area of interest because angiogenesis is involved in 
various physiological and pathological processes. (Donovan et al., 2001) 
 
1.3.1 In vivo angiogenesis assays 
 
In vivo angiogenesis assays give the most exact information of vascular events because they mimic 
angiogenesis as it occurs in normal environment. But there is still some disadvantages: they are 
usually expensive and more difficult to carry trough. They involve multiple cell types and potential 
metabolic processing of the studied agent, which complicates the analysis of the agent’s mechanism 
of action. (Goodwin, 2007) In vivo tests are mainly animal tests, which do not necessarily predict 
effects in human but they still are used widely. (Sarkanen et al., 2011) 
 
1.3.2 In vitro angiogenesis assays 
 
In vitro angiogenesis assays are important tool of studying mechanisms of angiogenesis and also 
potential equipment to develop therapeutic strategies of vascularization. (Donovan et al., 2001) 
Because there are so many factors which regulate the angiogenesis (hormones, cytokines, hypoxia, 
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shear stress), in vitro assays never are entirely adequate. (Auerbach, 2008) Even though in vitro 
angiogenesis assay does not cover every step of angiogenesis process, it effectively mimics the key 
steps i.e. migration and differentiation of endothelial cells. (Sarkanen et al., 2011) It also allows 
identification of direct effects on studied cell function. There is no need for technical expertise in 
animal handling, which is required in vivo assays. (Goodwin, 2007) There is strong need for pre-
validated human cell in vitro assays for reducing and replacing animal tests. (Sarkanen et al., 2011) 
 
Before in vitro assays can be used to make regulatory decisions they must undergo a validation 
process which evaluates its reliability, relevance and fitness for purpose. Nowadays the validation 
means that the new test must provide equivalent or better way to do things than current procedures. 
Parameters which are evaluated are time, money and the process of making. (Judson et al., 2013) 
 
Sarkanen et al. have studied angiogenesis assay, in which human foreskin fibroblast and human 
umbilical vein endothelial cell (HUVECs) co-cultivation was exposed to six reference chemicals. 
Chemicals were widely used pharmaceuticals that inhibit angiogenesis and their effect in human was 
known. The test results showed that a standardized in vitro angiogenesis assay mimics well the effects 
in man and it is reliable way to test angiogenesis modulators. (Sarkanen et al., 2011) Later Sarkanen et 
al. have also studied hASC+HUVEC co-culture angiogenesis assay in which cells are induced with 
natural growth factors and allowed to self-assemble into tubular network and vascular supporting 
structures. It provides completely human-based and simplified model of angiogenesis and it could be 
used for studying angiogenesis in vitro (Sarkanen et al., 2012).  
 
1.4 Chemicals and blood vessels 
 
1.4.1 Angiogenesis in cancer 
 
Angiogenesis has become an attractive target for drug therapy because angiogenesis is a key process 
to tumor growth and many compounds are in pre-clinical development constantly. Physiologic 
angiogenesis is tightly regulated and organized by anti- and pro-angiogenic factors but in tumors new 
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blood vessels are irregular and leaky. The tumor endothelial cells divide more rapidly and express 
different markers. (Cook and Figg, 2010) Because endothelial cells line the vessels, they are better 
target to anti-cancer drugs than tumor cells themselves meaning that angiogenesis inhibitor therapy 
may prevent tumor growth instead of killing tumors.  That is why angiogenesis inhibitors are most 
effective when combined with additional therapies. (Yoo and Kwon, 2013) When targeting tumor 
blood vessels with anti-cancer compounds, there are two strategies. First is anti-angiogenic therapy, 
where new blood vessel formation is inhibited. That has almost none effect on blood vessels that 
already exists. That is why effect on large tumors is very limited. The second strategy is vascular 
disrupting therapy (VDT), in which rapid and selective shutdown of already existing vasculature 
happens. It disrupts the tumor endothelium selectively, because it founds the difference between 
immature tumor vasculature and normal mature blood vessel. It has greater power in bigger tumors, 
but it has no effect on angiogenesis, which happens vigorously in tumor periphery. (Xuan et al., 2009) 
 
One interesting finding is that many conventional chemotherapeutics actually possess previously 
unknown anti-angiogenesis activity. (Cook and Figg, 2010) Solid tumors often suffer from hypoxia, 
extracellular acidosis and nutrient deprivation which can lead to inflammatory response. That is why 
solid tumors often exhibit pro-inflammatory modules such as prostaglandins. Prostaglandins impact 
cancer cell behavior such as motility, invasion, vascularization and metastatic dissemination. Non-
steroidal anti-inflammatory drugs (NSAIDs) can reduce inflammation by inhibiting COX activity and 
that is why NSAIDs are widely studied as anti-cancer agents. (Ackerstaff et al., 2007) 
 
1.4.2 Other angiogenesis involving diseases 
 
There are also other diseases than cancer where angiogenesis plays a central role. In a field of 
ophthalmology anti-angiogenic strategies are also used because VEGF have been implicated as a 
major factor in ocular angiogenesis including pathological processes such as proliferative diabetic 
retinopathy, neovascular AMD and neovascular glaucoma, which causes blindness. Pegaptanib was 
the first anti-VEGF agent specifically designed for intraocular use and after that several other 
intraocular anti-VEGFs have been approved. (SooHoo et al., 2014) In psoriasis, hypervascular skin 
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lesions overexpress angiogenic polypeptide IL8 and underexpress the angiogenic inhibitor 
thrombospondin 1. Other diseases where the therapeutic goal is inhibition of angiogenesis are 
hemangiomas, Kaposi’s sarcoma, rheumatoid arthritis, endometriosis and atherosclerosis. (Yoo and 
Kwon, 2013) 
 
Stimulation of angiogenesis can also be a therapeutic goal. Such situation can be a need for collateral 
vessel formation for example in myocardial, peripheral or cerebral ischemia. In ischemia collateral 
vessels can improve blood supply to the area. Unfortunately currently there are no FDA-approved 
angiogenic drugs to treat ischemic cardiovascular disease. Stimulation of angiogenesis can also be 
needed in wound healing and reconstructive surgery. (Yoo and Kwon, 2013) 
 
1.5 Chemicals as vascular disrupting compounds during embryo development 
 
There is a large scale of chemicals which are known to be toxic for developing embryo. Some of them 
are medical drugs, such as thalidomide, estrogens, endothelins. For some time now also cigarette 
smoke is known to be toxic. (Knudsen and Kleinstreuer, 2011) Recently there have come out more 
knowledge concerning environmental chemicals acting also as vascular disrupting chemicals. 
Environmental chemicals are large and homogenous group of chemicals including food additives, 
plastic fillers and wide range of non-medical dugs. (Kleinstreuer et al., 2011)   
 
The first organ system which begins to function in embryo during development is cardiovascular 
system.  Cardiovascular system develops in first trimester, in which developing organ systems are 
most vulnerable against chemicals which enter mother body. There are also other factors than the 
onset of exposure which effects the chemical’s capacity to disrupt embryogenesis such as dose, 
genetic susceptibility and chemical interactions with biological system. (Knudsen and Kleinstreuer, 
2011) The two ways of blood vessel formation are described above. If blood vessel formation is 
somehow disrupted it likely leads to prenatal loss, malformations, placenta complications and 
problems in neuron development. Thalidomide is one commonly known vascular disrupting chemical. 
It was earlier used widely among pregnant women against nausea. (Kleinstreuer et al., 2011) Now 
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when there is more knowledge about negative sides of environmental chemicals there are also more 
studies. Heinonen et al. have shown that Octyl gallate, Triclosan, 1-hydroxypyrine, Disulfiram and 
Diethanolamine inhibit vascular tubule formation even lower concentrations than they are cytotoxic. 
(Heinonen et al.) 
 
Typically chemical testing during pregnancy involves in vivo tests for pregnant animals such as rats 
and rabbits. These test mostly take time but are also not effective when only one compound can be 
tested at the time. Also zebrafish are used widely in in vivo tests but the results do not predict results 
in human embryo. Zebrafish embryo is so small that it can receive oxygen by passive diffusion even 
without blood vessels. But they cover better the field when blood vessel development is studied. 
(Knudsen and Kleinstreuer, 2011) 
 
Nowadays there is need for more effective toxicity screening and in vitro assays are answer to that 
need. There are also high-throughput screening assays in which thousands of chemicals can be tested 
rapidly against huge amount of molecular targets. (Knudsen and Kleinstreuer, 2011) 
 
1.6 Chemicals in this study 
 
Ten chemicals were chosen in this study. Almost all of them are commonly known chemicals and their 
effects on angiogenesis are studied before: reference data in animal and man is available. Levamisole 
is alkaline phosphatase inhibitor, which is used as anti-helminthic agent but has also been used for 
adjuvant chemotherapy of colorectal cancer. The anti-angiogenic mechanisms of levamisole is not yet 
known, but it induces an endothelial cluster morphology and that way may involve the VEGF signaling 
pathway. (Friis et al., 2013) Erlotinib is epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor, which has anti-cancer activity. It is used as treatment of lung cancer. (Cook and Figg, 2010) 
Suramin is a polysulfonated naphtylurea and is reported to inhibit endothelial cell proliferation and 
migration by binding to VEGF. Also neutralizing antibodies to VEGF (anti-VEGF) is known to be an 
effective angiogenesis inhibitor. (Friis et al., 2013) 2-Methoxyestradiol is a human metabolite of 
estradiol, which inhibits tubulin polymerization, destabilizes the microtubules and causes cell cycle 
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arrest. It has anti-angiogenic and proapoptotic propertias and it also inhibits cell proliferation and 
migration. (Cook and Figg, 2010) NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide) 
belongs to sulphonamide class and is a COX-2-selective inhibitor. It binds uniquely to the cyclo-
oxygenase channel. (Vecchia and Malkowski, 2011) Acetylsalicylic acid (ASA, aspirin) in a non-selective 
non-steroid anti-inflammatory drug (NSAID), which is used for treating pain and fever and also as anti-
thrombotic agent. Aspirin use is associated with decreased risk for several cancers e.g. colon cancer. (Pathi 
et al., 2012) Indomethacin belongs to group of drugs called indoleacetic acids and it is also a non-selective 
NSAID. (Ackrerstaff et al., 2007) Triclosan (2.2.4'-thrichloro-2'hydroxydiphenyl ether) in an 
antimicrobian combound used as a bacteriostat, fungisatat and deodorizer. It is used in several 
custom products for example sanitizing products like soaps, toothpaste and hairproducts. There is a 
lot of worries in overuse of triclosan both in health care and in environmental studies. (Stoker et al., 
2010) Pyridaben is a pyridazinone derivate and it is an acaricide and insecticide for control of mites 
and some insects. (Hajime et al., 1994) 
 
2 MATHERIALS AND METHODS 
 
 
The study was carried out in the spirit of GLP and according to FICAM’s SOPs when applicable. 
 
2.1 Test systems/cells used 
 
hASCs (several different Masterbanks, e.g. K73-hASC014 for constructing the angiogenesis model) 
were used. Cells have been isolated from stromal vascular fraction of adipose tissue (enzymatically 
with 0.1% collagenase I). Adipose tissue is received as a leftover material from surgeries. Utilization of 
human adipose stem cells used in this study has received an approved statement of Joint Municipal 
Authority of the Pirkanmaa Hospital District with ETL-code R003058.  Cells were used in the 
angiogenesis model at passages 2-3. 
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HUVECs (several different Masterbanks, e.g. HUVEC012 for constructing the angiogenesis model) 
were used. HUVEC have been isolated from human umbilical cord veins (enzymatically with 0.05% 
collagenase), which are obtained from scheduled cesarean sections. Utilization of endothelial cells 
used in this study has received an approved statement of Joint Municipal Authority of the Pirkanmaa 
Hospital District with ETL-code R08028. Cells were used in the angiogenesis model passage 4. 
 
2.2 Tested chemicals  
 
Ten chemicals were tested in this study: Erlotinib (Roche), Acetylic salicylic acid (ASA) (Sigma), 
Levamisole (Sigma), 2-methylestradiol (Sigma), Anti-VEGF (Sigma), Suramin sodium salt (Sigma), 
Triclosan (Sigma), NS398 (Sigma), Indomethacin (Sigma), Pyridaben (Sigma). 
 
2.3 Experimental procedure 
 
2.3.1 Cell cultivation 
 
Both hASCs and HUVECs were thawed and cultivated separately in 75 cm2 culture bottles until they 
were confluent. Cells were counted using Bürger’s chamber and living/dead cell ratio was determined 
by using Trypan Blue. Angiogenesis assay was built in the following manner. First hASCs were plated 
on the bottom of cultivation well. After they had attached properly HUVECs were seeded on top of 
them. The co-culture was allowed to grow for one day before any experiments. 
 
2.3.2 Exposing co-cultivation to chemicals 
 
Co-cultures were exposed to ten different chemicals and every concentration of each chemical was 
tested in at least two wells of co-culture. Chemicals were dissolved according to manufacturer’s 
instruction and then diluted in CSFM based stimulation medium. If chemical did not dissolve to 
medium it was first diluted to DMSO or ethanol. Dilution agents for each chemical are seen on table 1. 
Concentration of DMSO never exceeded 0.3%. Each well was exposed two times to same 
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concentration, both cultivation periods were three days. Cultivation medium/chemical was removed 
before new exposure. Every plate had also positive and negative control and also 0.3% diluent control 
if chemical did not dissolve to CSFM based stimulation medium. 
 
 
Table 1 ǀ Dilution agents for each chemical. If chemical did not dissolve straight to medium it was 
first diluted to DMSO or ethanol. Concentration of DMSO never exceeded 0.3%. 
Chemical 
name 
Erlotinib Suramin NS-398 ASA 
2-Methoxy-
estradiol 
Dilutive agent DMSO 
Stimulation 
medium 
DMSO 
Stimulation 
medium 
DMSO 
Chemical 
name 
Pyridaben Indomethacin Anti-VEGF Levamisole Triclosan 
Dilutive agent DMSO DMSO 
Stimulation 
medium 
Stimulation 
medium 
Ethanol 
 
2.3.3 Immunocytochemical staining 
 
Immunocytychemical staining was performed on sixth day after first exposure. Cells were fixed with 
ice-cold 70% ethanol and after that treated with 0.5 % Triton X-100 and blocked for unspecific 
staining with 10% BSA. Then cells were incubated with 120 µl of primary antibody, anti-von 
Willebrandt (produced in rabbit) and anti- Collagen IV (produced in mouse diluted in 1% BSA in PBS, at 
4°C overnight or 1 hour at room temperature. Cells were then incubated with secondary antibody 
(Anti-Rabbit IgG TRITC or anti-mouse IgG FITC, diluted with appropriate dilution ratio) for 30-45 min at 
room temperature in dark. 
 
2.3.4 Toxicity test 
 
The purpose of the test was to find out highest non-toxic concentration for each chemical. Different 
concentrations of each chemical were tested and WST-1 reagent was used to determine which 
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concentration gives the viability of 80 % or higher. WST-1 was performed according to manufacturer’s 
instructions and the chemical exposure time was 6 days. Absorbances were measured at 440 nm with 
plate reader after 1,5h of incubation in 37°C. WST-1 was performed on the same plate as 
immunostaining but before it.  
 
2.3.5 Result analysis 
 
After staining formed vessel tubes were graded in scale 0-10 and photographed with Cell-IQ with 10x 
enlargement. Examples of grades are seen in figure 1. Good positive and negative control are seen in 
figure 2. Results were analyzed and figures done from semi-quantitative and quantitative results. 
Resulting absorbances from toxicity test were measured with plate reader (VarioSkan, Thermo 
Scientific) and the values were processed with Microsoft Office Excel. Data handling was done with 
GraphPad Prism and photographs were processed with Adobe Photoshop CS6. 
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Figure 1 ǀ Blood vessel tubes were graded in scale 0-10. 0 = no tubule formation and 10 = good 
tubule formation, tubules connect each other and tubule network is constant. 
 
3 RESULTS 
 
 
Each chemical was tested as separate experiment and the data was collected each step of the 
process. Cell cultures were exposure to different concentrations of chemicals and cell toxicity test was 
done afterwards. EC80 value represents the concentration that gives the cell viability of 80 % or 
higher. Same concentrations were also used for determine each chemical’s potential to inhibit 
angiogenesis. IC50 value represents the concentration in which half of reactions are inhibited. All 
calculated data is collected in table 2.  
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Table 2 ǀ IC50 and EC80 values for each chemical. * = Value can not be calculated. ** = reference 
value not found. 
Chemical Erlotinib Suramin NS-398 ASA 
2-Methoxy-
estradiol 
IC50 6.316 µM 135.0 µM 323.6 µM 3.324 mM 720.6 µM 
IC50 in literature 
Moderate 
10 µM 
(Sarkanen et al., 
2012) 
100 µM 
(Friis et al., 2013) 
** 
500µM (Borthwick 
et al.,2006) 
250 µM (Friis et 
al., 2013) 
Moderate 50 
µM (Sarkanen et al., 
2012) 
EC80 ~0.7755 µM * * * 70.64 µM 
Chemical Pyridaben Indomethacin Anti-VEGF Levamisole Triclosan 
IC50 0.02395 µM 158.4 µM 6.382 µM 494.3 µM 31.66 µM 
IC50 in literature ** 
2.5 mM (Friis et 
al., 2013) 
Strong 5 µM 
(Sarkanenet al., 2012) 
Moderate 750-
1000 µM 
(Sarkanen et al., 2012) 
** 
EC80 * * 0.2047 µM ~1272 µM 18.04 µM 
 
EC80 value was not possible to calculate for every chemical meaning that those chemicals did not 
effect on cell viability with tested concentrations. In future further tests can be carried out with higher 
concentration. Even though they are not cell toxic they still have effect on angiogenesis. Only three 
quite reliable values were able to be calculated and those are with 2-methoxyestradiol, Anti-VEGF and 
Triclosan. For Levamisole and Erlotonib the calculated values are just estimates. 
 
IC50 value was possible to calculate for every chemical but there were situation where an extra 
concentration (10x compared to highest tested chemical concentration) had to be added for to have a 
good negative slope. In statistics, the same tubule value as in the highest tested concentration was 
added  to the extra concentration. In those cases the results are not as reliable as other values and 
even higher concentrations should be tested in future. This was the case with Suramin, NS-398 and 
Indomethacin. Results for each chemical will be described below. 
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3.1 Erlotinib 
 
EC80 value is only estimate and as seen in figure 2, the absorbance slope is not linear. Tubule 
formation gives good slope although positive control in this plate got only grade 5. 
 
 
Figure 2 ǀ Erlotinib tubule formation and WST-1 absorbance. 
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Figure 3 ǀ Erlotinib tubule formation. a = highest tested concentration 50 µM, b = 10 µM, c = 1 µM,  
d = smallest tested concentration 0.01 µM. In c tubule formation is better than on d. 
 
3.2 Suramin 
 
There was some challenges when evaluating tubule formation in experiment with Suramin. Cells 
should not grow in lumps and the tubule network should be constant. In some wells cells have made 
big lumps in the middle of well but on the sides there might have been good tubule formation. That 
made the evaluation challenging because that lowered the grade even when tubule formation was 
very good in sides of the well. Still the results are reliable when calculating the effects on 
angiogenesis, IC50 value is 135.0. Any results from toxicity test can’t be calculated because the 
absorbance actually rose with highest concentrations. 
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Figure 4 ǀ Suramin tubule formation and WST-1 absorbance. 
 
 
 
Figure 5 ǀ Suramin tubule formation. a = highest tested concentration 75 µM, b = 50 µM, c = 5 µM,  
d = smallest tested concentration 0.01 µM. B demonstrates the cell lumps which were seen in many 
wells. 
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3.3 NS-398 
 
NS-398 gives very disturbing slope from toxicity test and it is not reliable. It would be necessary to 
repeat the experiment for to get reliable results about toxicity. Results from angiogenesis test are 
more adequate giving IC50 value 323.6 and the slope is demonstrative but the results are not 
unambiguous as seen in figure 6. Even though the slope goes naturally downwards. 
 
 
Figure 6 ǀ NS-398 tubule formation and WST-1 absorbance. 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
  
 
 
Figure 7 ǀ NS-398 tubule formation. a = highest tested concentration 100 µM, b = 46 µM, c = 9.7 µM, 
d = smallest tested concentration 0.98 µM. The picture is not very informative because results were 
very simiral troughout the whole experiment. 
 
3.4 ASA 
 
When viewing the cells under the microscope after the first three days from chemical exposure there 
was some crystals seen in highest concentration. We can not be sure if it has affected on tubule 
formation because the grade was zero but it seems that crystals are not the only reason for bad grade 
because tubule formation was poor also with lower concentrations. Nevertheless, the slope is highly 
demonstrative. Based on WST-1 test absorbances it can be said that ASA is not toxic with tested 
concentrations. 
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Figure 8 ǀ ASA tubule formation and WST-1 absorbance. 
 
 
 
Figure 9 ǀ ASA tubule formation.  a = highest tested concentration 10 mM, b = 4 mM, c = 2 mM,  
d = smallest tested concentration 0.001 mM. Tubule formation was very poor when concentration 
was more than 2 mM. 
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3.5 2-Methoxyestradiol 
 
Tubule formation was good with small concentrations and grades did not differ from each other. With 
higher concentrations there was more variation between the wells of same concentrations. One 
explanation is that there was some lump formation in wells which lowered the grade. In toxicity the 
slope is highly informative.  
 
 
Figure 10 ǀ  2-Methoxyestradiol tubule formation and WST-1 absorbance. 
 
 
 
Figure 11 ǀ 2-Methoxyestradiol tubule formation.  a = highest tested concentration 2000 nM, b =  
smallest tested concentration 35.33 nM.  
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3.6 Pyridaben 
 
 
 
Figure 12 ǀ Pyridaben tubule formation and WST-1 absorbance. 
 
 
Figure 13 ǀ Pyridaben tubule formation. a = highest tested concentration 1.00 µM, b = 0.03 µM,  
c = 0.001 µM, d = smallest tested concentration 0.00001 µM. 
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3.7 Indomethacin 
 
Toxicity test gives no reliable results because cell viability rose with high concentration. Results from 
angiogenesis test gave more adequate data. Only down side is that positive control got lower grading 
than smallest tested indomethacin concentration.  
 
 
 
Picture 14 ǀ Indomethacin tubule formation and WST-1 absorbance. 
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Figure 15 ǀ Indomethacin tubule formation. a = highest tested concentration 200.00 µM,  
b = 63.29 µM, c = 20.30 µM, d = smallest tested concentration 0.002 µM. 
 
 
3.8 Triclosan 
 
In experiment with Triclosan positive control got only grade 6 but so did the smallest concentration of 
chemical. Slopes give good information in figure 16. 
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Figure 16 ǀ Triclosan tubule formation and WST-1 absorbance. 
 
 
 
Figure 17 ǀ Triclosan tubule formation. a = highest tested concentration 100 µM, b = 31.65 µM, 
c = 0.32 µM, d = smallest tested concentration 0.01 µM. Tubule formation were better in other 0.32 
µM well than with smallest concentration. Immunostaining is not so bright than in other plates. 
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3.9 Anti-VEGF 
 
Ficure 18 ǀ Anti-VEGF tubule formation and WST-1 absorbance. 
 
 
 
Figure 19 ǀ Anti-VEGF tubule formation. a = highest tested concentration 267.00 µM, b = 50.00 µM,  
c = 1.00 µM, d = smallest tested concentration 0.01 µM 
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3.10 Levamisole 
 
When evaluating the tubule formation in experiment with Levamisole, it turned out that there was 
plenty of cells and cell lumps growing in the middle of wells. There were also many wells where the 
cells were detached from the bottom of the plate on the left side of the well. One explanation for 
lumps can be inappropriate stirring when passaging the cells while doing angiogenesis assay. Too 
rough pipetting can explain the detachment of the cells from the left side. Both reasons clearly 
depends on person who did the experiment and that problem can be solved if further experiments 
are carried out. Nevertheless there was tubule formation outside the middle and the grading was 
done systematically from there. 
 
 
Figure 20 ǀ Levamisole tubule formation and WST-1 absorbance. 
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Figure 21 ǀ Levamisole tubule formation. a = highest tested concentration 3000 µM, b = 1000 µM,  
c = 0.01 µM, d = smallest tested concentration 0.0001 µM. Bright areas seen in the middle of wells. 
 
4 CONCLUSIONS 
 
 
There is strong need for pre-validated human cell in vitro assays for reducing and replacing animal 
tests. Animal tests do not necessarily predict effects in human but they still are used widely. 
(Sarkanen et al., 2011) In vitro angiogenesis assays are important tool of studying mechanisms of 
angiogenesis and also potential equipment to develop therapeutic strategies of vascularization. 
(Donovan et al., 2001) Even though they do not cover every step of angiogenesis process, they 
effectively mimic the key steps i.e. migration and differentiation of endothelial cells. (Sarkanen et al., 
2011) Nowadays there is high standards for in vitro assays and they must undergo validation process 
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before they can be taken in proper use. Reliability, relevance and fitness for purpose must be 
evaluated and the new test system should provide equivalent or better results than current 
procedures to even consider to become the new standard, time and money play central role. (Judson 
et al., 2013) 
 
Sarkanen et al. have studied hASC+HUVEC co-culture angiogenesis assay in which cells are induced 
with natural growth factors and allowed to self-assemble into tubular network and vascular 
supporting structures. It provides completely human-based and simplified model of angiogenesis. 
(Sarkanen et al., 2012) The aim of this study was to validate the hASC+HUVEC co-culture by exposing 
it to ten commonly known chemicals, which effects on angiogenesis have been studied before. We 
evaluated reliability, relevance and fitness for purpose by comparing the test results with results from 
literature and earlier studies. Also other side of validation was put under examination; is the test 
system repeatable and is the process of making worth of money and time spent. 
 
We tested both cell toxicity and effects on angiogenesis of each chemical to see if the effects are 
caused by specific anti-angiogenic property of the substance or if it is just common cell toxicity. 
Several different concentrations were tested and at least in two wells simultaneously. EC80 value was 
not possible to calculate for every chemical meaning that those chemicals did not affect on cell 
viability with tested concentrations. These chemicals found to have an effect specifically on 
angiogenesis. In future higher concentrations can be tested if there is a need to determine 
concentration which causes cell toxicity. IC50 value was calculated for every chemical but there were 
three chemicals for which extrapolation had to be used to be able to calculate the IC50 value. With 
Suramin, NS-398 and Indomethacin the results may not be accurate and even higher concentrations 
should be tested in future for to have even more reliable results.  
 
When comparing toxicity test results with previously known values there can be seen some 
difference. Some reference values could not be found (see table 2) and some are quite far from 
results from this study. However, test gave some IC50 values for each chemical. These things (result 
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differences) should be considered in the future and still more test need to be done to complete 
validation process of this in vitro angiogenesis assay. 
 
There were also some challenges to evaluate tubule formation completely adequate. The best scene 
should have been that cells did not grow in lumps and the tubule network should have been constant. 
For some chemicals lumps existed in several wells and with Levamisole there was also detachment of 
the cells from the left side of the well. Some reasons may depend on person who executed the 
experiments; not enough stirring while passaging the cells or too rough cell cultivation technique. If 
so, in the future these things should be considered. One explanation for lumps may just be chemical’s 
effect on cells; the chemical might be inhibiting the endothelial migration and for this reason proper 
tubule formation is not possible when exposed to chemical. 
 
When thinking overall the test process, there is one main point which comes out; it is mainly executed 
by human. The success of test results highly depend on person who executes the cell cultivation and 
chemical exposition. There are several steps when testing each chemical and also different cell 
cultivations must be done to every different chemical. Even though the test procedure is easy to 
learn, the executor must be trained to do cell cultivation. That is one way how different cell 
cultivations can be as alike as possible. It is also important that the same person does most of the 
work. Also the final evaluating of tubule formation is done by human, but the variation there is not so 
apparent because standards are already done for each grade and same person is executing the 
evaluation. The grading can be even more reliable if other person also does it.  
 
The final conclusion is, that this hASC+HUVEC co-culture angiogenesis assay has a lot of potential to 
become standard procedure when testing chemical effects on angiogenesis. Some more test need to 
be done in future to get more reliable results on toxicity tests to complete the validation process. 
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